tetano
Editor, Senior Moderator
Cytokine. 2010 Apr 26. [Epub ahead of print]
Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice.
Huang H, Li H, Zhou P, Ju D.
Department of Biosynthesis, School of Pharmacy, Fudan University, Shanghai, China.
Abstract
Protective effects of recombinant human granulocyte macrophage colony stimulating factor (rHuGM-CSF) on H1N1 influenza virus infection was studied in vivo and in vitro. Mice were infected with H1N1 influenza A viruses and rHuGM-CSF at doses of 0.34, 0.67, and 1.34mgkg(-1)d(-1) was administrated for 7days before the mice were infected with influenza virus and continued for a further 3days. Compared with control mice, rHuGM-CSF was demonstrated to increase the survival rate of the infected mice by 50.0%, 55.6%, and 80.0% and increased the mean survival days by 25.7%, 30.0%, and 46.8%, respectively. Histopathological study of the lungs in pneumonia mice found that pre-treatment with rHuGM-CSF significantly ameliorated lung injury induced by influenza virus infection. In vitro study demonstrated that when rHuGM-CSF were co-incubated with peripheral blood mononuclear cells (PBMCs), the PBMCs culture supernatant induced a dose-dependent reduction of virus-induced cytopathic effect (CPE) in Madin-Darby canine kidney (MDCK) cells in vitro. These results suggested that rHuGM-CSF might be an effective and potential protection for H1N1 influenza virus-induced pneumonia. Copyright ? 2010 Elsevier Ltd. All rights reserved.
PMID: 20427198 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20427198
Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice.
Huang H, Li H, Zhou P, Ju D.
Department of Biosynthesis, School of Pharmacy, Fudan University, Shanghai, China.
Abstract
Protective effects of recombinant human granulocyte macrophage colony stimulating factor (rHuGM-CSF) on H1N1 influenza virus infection was studied in vivo and in vitro. Mice were infected with H1N1 influenza A viruses and rHuGM-CSF at doses of 0.34, 0.67, and 1.34mgkg(-1)d(-1) was administrated for 7days before the mice were infected with influenza virus and continued for a further 3days. Compared with control mice, rHuGM-CSF was demonstrated to increase the survival rate of the infected mice by 50.0%, 55.6%, and 80.0% and increased the mean survival days by 25.7%, 30.0%, and 46.8%, respectively. Histopathological study of the lungs in pneumonia mice found that pre-treatment with rHuGM-CSF significantly ameliorated lung injury induced by influenza virus infection. In vitro study demonstrated that when rHuGM-CSF were co-incubated with peripheral blood mononuclear cells (PBMCs), the PBMCs culture supernatant induced a dose-dependent reduction of virus-induced cytopathic effect (CPE) in Madin-Darby canine kidney (MDCK) cells in vitro. These results suggested that rHuGM-CSF might be an effective and potential protection for H1N1 influenza virus-induced pneumonia. Copyright ? 2010 Elsevier Ltd. All rights reserved.
PMID: 20427198 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20427198